Atria Investments Inc Has $376,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Atria Investments Inc raised its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 41.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,137 shares of the biopharmaceutical company’s stock after acquiring an additional 1,497 shares during the quarter. Atria Investments Inc’s holdings in Intra-Cellular Therapies were worth $376,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Intra-Cellular Therapies by 1.4% in the first quarter. Vanguard Group Inc. now owns 9,225,981 shares of the biopharmaceutical company’s stock valued at $638,438,000 after acquiring an additional 131,679 shares during the last quarter. Avoro Capital Advisors LLC lifted its stake in Intra-Cellular Therapies by 21.2% in the second quarter. Avoro Capital Advisors LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock valued at $205,470,000 after acquiring an additional 525,000 shares during the last quarter. Perceptive Advisors LLC lifted its stake in Intra-Cellular Therapies by 62.6% in the second quarter. Perceptive Advisors LLC now owns 1,716,407 shares of the biopharmaceutical company’s stock valued at $117,557,000 after acquiring an additional 661,052 shares during the last quarter. Millennium Management LLC lifted its stake in Intra-Cellular Therapies by 214.5% in the second quarter. Millennium Management LLC now owns 889,102 shares of the biopharmaceutical company’s stock valued at $60,895,000 after acquiring an additional 606,358 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its stake in Intra-Cellular Therapies by 3.3% in the third quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company’s stock valued at $43,735,000 after acquiring an additional 18,865 shares during the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Down 0.2 %

NASDAQ:ITCI opened at $85.45 on Friday. The company has a fifty day moving average of $78.84 and a 200-day moving average of $74.58. The firm has a market capitalization of $9.06 billion, a P/E ratio of -98.22 and a beta of 0.97. Intra-Cellular Therapies, Inc. has a twelve month low of $58.14 and a twelve month high of $93.45.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The company had revenue of $175.40 million during the quarter, compared to the consensus estimate of $172.30 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business’s revenue was up 39.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.25) EPS. On average, analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ITCI. Morgan Stanley increased their price objective on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Piper Sandler raised shares of Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $68.00 to $92.00 in a research report on Friday, September 6th. UBS Group dropped their price objective on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. The Goldman Sachs Group dropped their price objective on shares of Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $130.00 price objective on shares of Intra-Cellular Therapies in a research report on Monday, September 16th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, Intra-Cellular Therapies currently has an average rating of “Moderate Buy” and a consensus price target of $97.23.

Insider Buying and Selling at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 40,513 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $73.58, for a total value of $2,980,946.54. Following the transaction, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at approximately $78,754,807.82. The trade was a 3.65 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Michael Halstead sold 22,869 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total transaction of $2,038,085.28. The disclosure for this sale can be found here. In the last 90 days, insiders sold 97,778 shares of company stock worth $7,524,436. 2.60% of the stock is owned by corporate insiders.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.